TMPRSS2-ERG fusion is frequently observed in gleason pattern 3 prostate cancer in a canadian cohort
TMPRSS2-ERG fusion is frequently observed in gleason pattern 3 prostate cancer in a canadian cohort
复制标题
DOI：
10.4161/cbt.8.2.7134
复制
发表时间：
2009-01-01
影响因子：
3.6
通讯作者：
Bismar, Tarek A.
中科院分区：
文献类型：
--
作者：
Darnel, Andrew D.;LaFargue, Christopher J.;Bismar, Tarek A.
目的：TMPRSS 2-ERG基因融合是前列腺癌（PCA）最常见的基因重排。TMPRSS 2-ERG基因融合状态在相同的癌灶内是同质的，并且82%的融合阳性PCA存在于GS 6或7中，而GS 8中为14%（p = 0.004）。此外，TMPRSS 2-ERG融合存在于42%的Gleason模式3对27%的Gleason模式4中（p = 0.014）。然而，在本研究中，TMPRSS 2-ERG融合状态与病理分期、手术切缘或生化失败之间无显著相关性。实验设计：采用分离FISH法间接评估TMPRSS 2-ERG融合。我们试图描述的发病率，病理特征和TMPRSS 2-ERG基因融合的196名加拿大男子根治性切除术治疗局部PCA的临床参数，并探讨其作为生物标志物在PCA.Conclusion：较高的关联TMPRSS 2-ERG与Gleason评分6和7应进一步研究。如果得到证实，如果TMPRSS 2-ERG被证实为预后生物标志物，则这可能对进一步分层PCA患者具有显著的临床影响。
Purpose: TMPRSS2-ERG gene fusion was recently reported as the most common gene rearrangement in prostate cancer (PCA).Results: In this cohort 41% of the patients showed positive gene fusion status in their PCA. The TMPRSS2-ERG gene fusion status was homogenous within the same cancer focus and 82% of fusion positive PCA were present in GS 6 or 7 vs. 14% in GS 8 ( p = 0.004). Moreover, TMPRSS2-ERG fusion was present in 42% of Gleason pattern 3 vs. 27% of Gleason pattern 4 ( p = 0.014). However, in this study, no significant association was noticed between TMPRSS2-ERG fusion status in relation to pathological stage, surgical margin or biochemical failure.Experimental design: Using break-apart FISH assay to indirectly assess the fusion of TMPRSS2-ERG. We sought to characterize the incidence, pathological features and clinical parameters of TMPRSS2-ERG gene fusion in a cohort of 196 Canadian men treated by radical prostatectomy for localized PCA, and to investigate its potential as a biomarker in PCA.Conclusion: The higher association of TMPRSS2-ERG with Gleason score 6 and 7 should be further investigated. If confirmed, this could have significant clinical impact in further stratifying patients with PCA should the TMPRSS2-ERG be confirmed as a prognostic biomarker.